Core Insights - The company, jointly known as Gongtong Pharmaceutical, is a leading supplier of steroid drug starting materials and is expanding its operations along the entire industry chain, focusing on high-end steroid APIs and formulations [2][3] Industry Positioning - Steroid drugs are the second largest category of pharmaceuticals after antibiotics, with extensive clinical applications [2] - Gongtong Pharmaceutical is recognized as a "source factory" for steroid drugs, producing starting materials and intermediates, with a market share exceeding 60% in the starting material sector [2] Strategic Expansion - The company aims to become the first domestic supplier to cover the entire range of steroid APIs, including sex hormones, progestogens, and corticosteroids, achieving a seamless integration from starting materials to APIs [3] - Gongtong Pharmaceutical has established a dual-driven core competitiveness through technological advancements and cost-effective vertical integration [3] Focus on Reproductive Health - The company is actively involved in the reproductive health sector, producing intermediates for sex hormones and progestogens, with new production capacity supporting 60% of the national demand for progesterone [5] - Future plans include a full industry chain layout in reproductive health, from raw material supply to direct consumer engagement [5] Technological Advancements - The company is leveraging advanced technologies such as synthetic biology and green chemistry to enhance production efficiency and product quality [5][6] - Continuous R&D investment is directed towards high-growth areas like anti-cancer drugs and reproductive health medications [6] International Expansion - Gongtong Pharmaceutical's overseas sales have been increasing, projected to contribute 60%-70% of revenue in the future, with a current overseas sales ratio of 28.54% expected to rise to 38.6% by mid-2025 [7] - The company plans to enhance its international presence through local partnerships and joint ventures to overcome market entry barriers [7] Long-term Vision - The company envisions a significant market opportunity in the next decade, driven by advancements in synthetic biology and targeted delivery technologies, particularly in cancer treatment and gene therapy [8] - Short-term strategies focus on adopting green production methods to address environmental and cost challenges, while mid-term goals include overcoming technical barriers in high-end formulations [8]
共同药业董事长系祖斌：布局甾体药物全链条 锻造长期竞争力